155 related articles for article (PubMed ID: 7816754)
1. Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro.
Guchelaar HJ; de Vries EG; Meijer C; Esselink MT; Vellenga E; Uges DR; Mulder NH
Pharm Res; 1994 Sep; 11(9):1265-9. PubMed ID: 7816754
[TBL] [Abstract][Full Text] [Related]
2. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
3. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Los G; van Vugt MJ; den Engelse L; Pinedo HM
Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
6. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
7. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
8. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
10. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
12. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
[TBL] [Abstract][Full Text] [Related]
13. Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.
Courjault F; Leroy D; Coquery L; Toutain H
Arch Toxicol; 1993; 67(5):338-46. PubMed ID: 8396390
[TBL] [Abstract][Full Text] [Related]
14. [Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line].
Yoshizumi N; Fujiwara J; Yoshizaki A; Sato M; Sakai R; Nishiya I
Hum Cell; 1988 Sep; 1(3):301-7. PubMed ID: 2979207
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
17. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
Hong WS; Kim HT; Kim KH; Kim DK
Anticancer Res; 1995; 15(1):51-4. PubMed ID: 7733640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
